文献速递前列腺癌男科与性医学

接受阿帕他胺治疗的非转移性去势抵抗性前列腺癌患者跌倒相关临床特征

Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-10-08

该事后分析纳入SPARTAN研究中随机接受阿帕他胺联合持续雄激素剥夺治疗的806例非转移性去势抵抗性前列腺癌患者,分析跌倒相关临床变量。803例可评估患者中125例(15.6%)报告跌倒,多数为1-2级且无需住院,随机化至首次跌倒中位时间9.2个月(范围0.1-25.3个月)。多变量模型显示基线高龄、ECOG体力状况差、神经病变史及研究治疗前使用α受体阻滞剂与跌倒显著相关,基线后发生神经病变、关节痛和跌倒前体重下降与跌倒时间显著相关。

要点

  • 阿帕他胺联合ADT治疗患者中15.6%(125/803)报告跌倒,多数为1-2级且无需住院。
  • 基线高龄、ECOG体力状况差、神经病变史及研究治疗前α受体阻滞剂使用与跌倒显著相关。
  • 基线后发生神经病变、关节痛和跌倒前体重下降与跌倒时间显著相关。

核心结论

  • 该分析识别了接受阿帕他胺治疗的nmCRPC患者跌倒的危险因素,临床管理可尽量降低这些已识别风险并改善患者结局。
  • 作者认为,当存在已识别的基线状况及治疗后神经病变、关节痛或体重下降时,应考虑预防性干预以降低跌倒风险。

研究设计与样本

  • SPARTAN研究的事后分析,纳入随机分配至阿帕他胺组并接受阿帕他胺联合持续雄激素剥夺治疗的806例nmCRPC患者。
  • 采用Cox比例风险模型评估至跌倒时间,校正基线特征和时间变化因素,统计推断基于最终多变量模型。
  • 试验注册号ClinicalTrials.gov:NCT01946204。

主要发现

  • 803例接受阿帕他胺联合ADT治疗的患者中125例(15.6%)报告跌倒,多数为1级或2级且无需住院。
  • 随机化至首次跌倒的中位时间为9.2个月(范围0.1-25.3个月)。
  • 在同时纳入基线和基线后协变量的最终多变量模型中,基线高龄、ECOG体力状况差、神经病变史和研究治疗前使用α受体阻滞剂仍与跌倒显著相关。
  • 基线后与至跌倒时间显著相关的临床特征为发生神经病变、关节痛和跌倒前体重下降。

临床怎么用

  • 作者认为,当存在已识别的基线状况及治疗后神经病变、关节痛或体重下降时,应考虑预防性干预以降低跌倒风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phase III SPARTAN study demonstrated that apalutamide significantly improves metastasis-free survival and overall survival vs. placebo in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). However, patients receiving apalutamide experienced falls more frequently vs. those receiving placebo (15.6% vs. 9.0%). METHODS: 806 patients with nmCRPC randomized to apalutamide in SPARTAN and treated with apalutamide in addition to ongoing androgen deprivation therapy (ADT) were included in this post-hoc analysis investigating clinical variables associated with a subsequent fall. Time to a fall was assessed with Cox proportional-hazards models adjusted for baseline characteristics and time-varying factors. Statistical inference was based on final multivariable models. RESULTS: Falls were reported for 125/803 (15.6%) patients treated with apalutamide and ADT. Most falls were grade 1 or 2 and did not require hospitalization. Median time from randomization to first fall was 9.2 months (range 0.1-25.3 months). In the final multivariable model of both baseline and after-baseline covariates, baseline patient characteristics (older age, poor Eastern Cooperative Oncology Group performance status, history of neuropathy, and α-blocker use before study treatment) remained significantly associated with fall; after-baseline clinical characteristics significantly associated with time to fall were development of neuropathy, arthralgia, and weight loss before fall. CONCLUSIONS: This analysis identified risk factors for fall among nmCRPC patients treated with apalutamide. Clinical management can minimize these identified risks while enhancing patient outcomes. Preventive interventions should be considered when the identified baseline conditions and post-treatment neuropathy, arthralgia, or weight decrease are present, to reduce risk of fall. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01946204.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Pollock Y, Smith MR, Saad F, et al. Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide. Prostate Cancer Prostatic Dis. 2022. PMID: 36209239. doi:10.1038/s41391-022-00592-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。